+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Relapsing Refractory Multiple Myeloma - Market Insights, Epidemiology and Market Forecast - 2028

  • ID: 4845170
  • Drug Pipelines
  • 265 pages
  • DelveInsight
UP TO OFF
until Dec 31st 2019
1 of 2
‘Relapsing Refractory Multiple Myeloma- Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Relapsing Refractory Multiple Myeloma in Asia (China and Taiwan), Middle East (Saudi Arabia and UAE), Eastern Europe (Russia and Turkey) and LATAM (Mexico, Brazil, Argentina and Columbia).

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Relapsing Refractory Multiple Myeloma from 2017 to 2028 segmented by ten emerging markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
  • Asia (China and Taiwan)
  • Middle East (Saudi Arabia and UAE)
  • Eastern Europe (Russia and Turkey)
  • LATAM (Mexico, Brazil, Argentina and Columbia)
Study Period:2017-2028

Relapsing Refractory Multiple Myeloma - Disease Understanding and Treatment Algorithm

Multiple Myeloma (MM) is the second most incident hematological malignancy worldwide, with a median onset of 60 years. This incurable malignancy develops from an accumulation of terminally differentiated monoclonal plasma cells (PC) in the bone marrow. The mechanism of action of MM characterized by the unusual increase of monoclonal paraprotein leading to evidence of specific end-organ damage. The majority of patients with multiple myeloma (MM) will have an initial response to treatment with modern combination regimens. However, conventional therapy is not curative and most of these patients will ultimately progress. In addition, some patients will not respond to initial treatment (i.e., refractory disease). Relapsed or refractory MM is usually identified through routine monitoring with laboratory studies. The signs and symptoms of Multiple Myeloma include hypercalcemia, renal insufficiency, anemia, lytic bony lesions along with a monoclonal protein in the serum, increase in the number of clonal plasma cells in the bone marrow, etc.

The Relapsing Refractory Multiple Myeloma market report gives the thorough understanding of the Relapsing Refractory Multiple Myeloma by including details such as disease introduction, symptoms of multiple myeloma, molecular classification of Multiple Myeloma, stages of multiple myeloma, pathogenesis, pathophysiology, biomarkers for multiple myeloma, diagnosis and patient-related risk factors.

Relapsing Refractory Multiple Myeloma Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Relapsing Refractory Multiple Myeloma in 10 EM covering Asia (China and Taiwan), Middle East (Saudi Arabia and UAE), Eastern Europe (Russia and Turkey) and LATAM (Mexico, Brazil, Argentina and Columbia) from 2017-2028 for the following aspects:
  • Diagnosed Incident cases of Multiple Myeloma (MM)
  • Gender-specific Diagnosed Incidence of Multiple Myeloma (MM)
  • Diagnosed Incident Multiple Myeloma (MM) Population on Second Line of Treatment
  • Diagnosed Incident Multiple Myeloma (MM) Population on Third Line (and above) of Treatment
  • Total Diagnosed Incident RRMM cases
There are several potential research papers and studies evaluated in order to analyze the overall epidemiology trend in the emerging markets. Few are listed below:

Lu et al. conducted a study “Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis” with the aim to understand the clinical features and treatment outcome of Chinese patients with multiple myeloma (MM). As per the study, if the Japanese incidence of MM is applied to China, there would be an estimated 27,800 new cases (1.39 billion × 2 per 100,000) each year and a total of 200,000 cases in China. With the acceleration of the aging process in China, it is predicted that MM, with rapid growth in incidence, will become one of the more significant diseases that affect people's health in the country. It has also been reported that immigrants from Asia living in the USA have an increased incidence of MM compared with those living in Asia.

Hungria et al. suggest that Multiple Myeloma (MM) is a disorder characterized by abnormal clonal proliferation of plasmocytes in the bone marrow resulting in the production of monoclonal immunoglobulins associated with organic disorders. MM accounts for 1% of all neoplastic diseases and 13% of hematologic neoplasms as stated in “Guidelines on the diagnosis and management of multiple myeloma treatment: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular Project guidelines: Associação Médica Brasileira - 2012.” In Brazil, there is no exact knowledge of the incidence of this disease.

Relapsing Refractory Multiple Myeloma Drug Chapters

This segment of the Relapsing Refractory Multiple Myeloma report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

To meet the increasing demand for the treatment of Relapsing Refractory Multiple Myeloma, companies have shifted their focus towards the development of targeted therapies. Expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the incident population of Relapsing Refractory Multiple Myeloma & awareness of the disease. The overall dynamics of Relapsing Refractory Multiple Myeloma market is anticipated to change in the coming years owing to the expected launch of emerging therapies of the major key players such as Oncopeptides, Celgene/Bluebird Bio, Sanofi, Legend Biotech Biotech/Janssen Biotech, GlaxoSmithKline, Pharmacyclics and Karyopharm Therapeutics will significantly increase the market during the forecast period (2019-2028).

Relapsing Refractory Multiple Myeloma Market Outlook

Multiple Myeloma (MM) is a blood cancer affecting plasma cells. The malignant plasma cells show metastases aggravating the problem. In some cases, cancer returns after the treatment or after a period of remission. Most of the patients relapse at some point due to lack of specific cure. Adding worries to myeloma condition, some patients do not respond to the therapy (or sometimes respond to initial treatment, but not to the treatment following a relapse) thereby becoming refractory, and hence known as Relapsing Refractory Multiple Myeloma (RRMM).

The market holds a diverse range of therapeutic alternatives for treatment, including Proteasome Inhibitors, Immunomodulating Agents, Histone Deacetylase (HDAC) inhibitors, Monoclonal Antibodies, Chemotherapy, Corticosteroids, and Nuclear export inhibitors in different lines of treatment. The treatment pattern lays more focus on second line of therapy and above for RRMM. Proteasome Inhibitors (PIs) forms a widely used class for treatment, including Bortezomib (Velcade), Carfilzomib (Kyprolis), and Ixazomib (Ninlaro). Proteasome inhibitors work by inhibiting enzyme complexes (proteasomes) in cells from breaking down proteins important for controlling cell division. PIs affect tumor cells more than normal cells but also accompanies few side effects. The next in the list is Immunomodulators (IMiDs), including Thalidomide (Thalomid), Lenalidomide (Revlimid), and Pomalidomide (Pomalyst/Imnovid). IMiDs possess pleiotropic anti-myeloma properties, including immune-modulation, anti-angiogenic, anti-inflammatory, and anti-proliferative effects. IMiDs can increase the blood-clotting risk, thereby often given along with aspirin or a blood thinner. The treatment regime also includes Histone Deactylase (HDAC) Inhibitors affecting active genes or by interacting with proteins in chromosomes called histones. Panobinostat (Farydak) is an HDAC inhibitor used to treat patients who have already been treated with bortezomib and an immunomodulating agent. Monoclonal Antibodies have gained great popularity for the treatment of myeloma. Antibodies are proteins made by the body's immune system to help fight infections. Man-made versions (monoclonal antibodies), can be designed to attack a specific target, such as proteins on the surface of myeloma cells. mAbs used for the treatment of RRMM include Daratumumab (Darzalex) and Elotuzumab (Empliciti). The other treatment alternatives comprise Chemotherapy drugs and Corticosteroids.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to this report, the market of Relapsing Refractory Multiple Myeloma in 10 EM is expected to change from 2019-2028.

Relapsing Refractory Multiple Myeloma Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Expected launch of therapies for Relapsing Refractory Multiple Myeloma such as Melflufen (Oncopeptides), Idecabtagene vicleucel (Celgene/Bluebird), Isatuximab (Sanofi), JNJ-68284528 (Legend Biotech Biotech/Janssen Biotech), GSK2857916 (GlaxoSmithKline), Ibrutinib (Pharmacyclics) and Xpovio (Karyopharm Therapeutics) targeted therapies in the forecast period [2019-2028] will also create a positive impact on the Relapsing Refractory Multiple Myeloma market. Although approved only in the United States, the drug has not been launched in the emerging markets, therefore considered as an emerging therapy in this region.

Relapsing Refractory Multiple Myeloma Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Relapsing Refractory Multiple Myeloma Report Key Strengths
  • 10 Year Forecast
  • 10 EM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Relapsing Refractory Multiple Myeloma Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving Relapsing Refractory Multiple Myeloma market
  • Organize sales and marketing efforts by identifying the best opportunities for Relapsing Refractory Multiple Myeloma market
  • To understand the future market competition in the Relapsing Refractory Multiple Myeloma market.
Note: Product cover images may vary from those shown
2 of 2
1. Key Insights

2. Relapsing Refractory Multiple Myeloma Market Overview at a Glance
2.1. Market Share (%) Distribution of Relapsing Refractory Multiple Myeloma in 2017
2.2. Market Share (%) Distribution of Relapsing Refractory Multiple Myeloma in 2028
2.3. Region-Wise Comparison of Market Share
2.3.1. East Asia
2.3.2. Middle East
2.3.3. Eastern Europe
2.3.4. Latin America

3. Disease Background and Overview: Relapsing Refractory Multiple Myeloma (RRMM)
3.1. Introduction
3.2. Symptoms of multiple myeloma
3.3. Molecular Classification of Multiple Myeloma
3.4. Stages of Multiple Myeloma
3.5. Diagnosis of Multiple Myeloma
3.6. Pathogenesis of Multiple Myeloma
3.6.1. Molecular mechanisms underlying the progression of multiple myeloma
3.6.2. Molecular pathogenesis of multiple myeloma and its premalignant precursor
3.7. Pathophysiology of Multiple Myeloma
3.8. Biomarkers for Multiple Myeloma
3.8.1. Serum M-protein and light chains as biomarkers
3.8.2. Potential proteomic biomarkers
3.8.3. Cytogenetic biomarkers in multiple myeloma
3.9. Patient-related risk factors
3.10. Factors influencing the choice of therapy at relapse
3.11. Nutshell of Multiple Myeloma

4. Epidemiology and Patient Population: Key Findings
4.1. 10 EM Total Diagnosed Incident Patient Population of Relapsing Refractory Multiple Myeloma

5. Country Wise-Epidemiology of Relapsing Refractory Multiple Myeloma
5.1. East Asia: China and Taiwan
5.1.1. Assumptions and Rationale
5.2. China
5.2.1. Multiple Myeloma (MM) Diagnosed Incident cases in China
5.2.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in China
5.2.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in China
5.2.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in China
5.2.5. RRMM Total Diagnosed Incident cases in China
5.3. Taiwan
5.3.1. Multiple Myeloma (MM) Diagnosed Incident cases in Taiwan
5.3.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Taiwan
5.3.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Taiwan
5.3.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Taiwan
5.3.5. RRMM Total Diagnosed Incident cases in Taiwan
5.4. Middle East: Saudi Arabia and United Arab Emirates
5.4.1. Assumptions and Rationale
5.5. Saudi Arabia
5.5.1. Multiple Myeloma (MM) Diagnosed Incident cases in Saudi Arabia
5.5.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Saudi Arabia
5.5.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Saudi Arabia
5.5.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Saudi Arabia
5.5.5. RRMM Total Diagnosed Incident cases in Saudi Arabia
5.6. United Arab Emirates
5.6.1. Multiple Myeloma (MM) Diagnosed Incident cases in United Arab Emirates
5.6.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in United Arab Emirates
5.6.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in United Arab Emirates
5.6.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in United Arab Emirates
5.6.5. RRMM Total Diagnosed Incident cases in United Arab Emirates
5.7. Eastern Europe: Russia and Turkey
5.7.1. Assumptions and Rationale
5.8. Russia
5.8.1. Multiple Myeloma (MM) Diagnosed Incident cases in Russia
5.8.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Russia
5.8.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Russia
5.8.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Russia
5.8.5. RRMM Total Diagnosed Incident cases in Russia
5.9. Turkey
5.9.1. Multiple Myeloma (MM) Diagnosed Incident cases in Turkey
5.9.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Turkey
5.9.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Turkey
5.9.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Turkey
5.9.5. RRMM Total Diagnosed Incident cases in Turkey
5.10. Latin America (LATAM): Argentina, Brazil, Colombia, Mexico
5.10.1. Assumptions and Rationale
5.11. Mexico
5.11.1. Multiple Myeloma (MM) Diagnosed Incident cases in Mexico
5.11.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Mexico
5.11.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Mexico
5.11.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Mexico
5.11.5. RRMM Total Diagnosed Incident cases in Mexico
5.12. Brazil
5.12.1. Multiple Myeloma (MM) Diagnosed Incident cases in Brazil
5.12.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Brazil
5.12.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Brazil
5.12.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Brazil
5.12.5. RRMM Total Diagnosed Incident cases in Brazil
5.13. Argentina
5.13.1. Multiple Myeloma (MM) Diagnosed Incident cases in Argentina
5.13.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Argentina
5.13.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Argentina
5.13.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Argentina
5.13.5. RRMM Total Diagnosed Incident cases in Argentina
5.14. Colombia
5.14.1. Multiple Myeloma (MM) Diagnosed Incident cases in Colombia
5.14.2. Multiple Myeloma (MM) Gender-specific Diagnosed Incidence in Colombia
5.14.3. Multiple Myeloma (MM) Diagnosed Incident Population on Second Line of Treatment in Colombia
5.14.4. Multiple Myeloma (MM) Diagnosed Incident Population on Third Line (and above) of Treatment in Colombia
5.14.5. RRMM Total Diagnosed Incident cases in Colombia

6. Treatment
6.1. Chemotherapy
6.2. Proteasome inhibitors
6.3. Immunomodulatory Agents
6.4. Monoclonal Antibodies
6.5. For Refractory/Relapsed Disease
6.5.1. Supportive care
6.5.2. Management of complications (CRAB and others)
6.5.3. Monitoring during and after therapy
6.5.4. Treatment of recurrences
6.6. Management

7. Treatment Algorithm

8. Unmet needs

9. Marketed Drugs
9.1. Pomalyst/Imnovid: Celgene
9.1.1. Drug Description
9.1.2. Regulatory Milestones
9.1.3. Other Development Activities
9.1.4. Safety and Efficacy
9.1.5. Pipeline Activity
9.1.6. Product Profile
9.2. Revlimid (Lenalidomide): Celgene
9.2.1. Drug Description
9.2.2. Regulatory Milestones
9.2.3. Other Development Activities
9.2.4. Safety and Efficacy
9.2.5. Pipeline Activity
9.2.6. Product Profile
9.3. Empliciti (Elotuzumab): Bristol-Myers Squibb
9.3.1. Drug Description
9.3.2. Regulatory Milestones
9.3.3. Other Development Activities
9.3.4. Safety and Efficacy
9.3.5. Product Profile
9.4. Thalomid (Thalidomide): Celgene
9.4.1. Drug Description
9.4.2. Regulatory Milestones
9.4.3. Other Development Activities
9.4.4. Safety and Efficacy
9.4.5. Product Profile
9.5. Darzalex: Janssen Biotech
9.5.1. Drug Description
9.5.2. Regulatory Milestones
9.5.3. Other Development Activities
9.5.4. Safety and Efficacy
9.5.5. Pipeline Activity
9.5.6. Product Profile
9.6. Kyprolis: Amgen
9.6.1. Drug Description
9.6.2. Regulatory Milestones
9.6.3. Other Development Activities
9.6.4. Safety and Efficacy
9.6.5. Pipeline Activity
9.6.6. Product Profile
9.7. Velcade: Millennium Pharmaceuticals (Takeda)
9.7.1. Drug Description
9.7.2. Regulatory Milestones
9.7.3. Other Development Activities
9.7.4. Safety and Efficacy
9.7.5. Post-marketing study
9.7.6. Product Profile
9.8. Mozobil: Genzyme
9.8.1. Drug Description
9.8.2. Regulatory Milestones
9.8.3. Other Development Activities
9.8.4. Safety and Efficacy
9.8.5. Product Profile

10. Emerging Drugs
10.1. Key Cross Competition
10.2. Melflufen: Oncopeptides
10.2.1. Product Description
10.2.2. Other Developmental Activities
10.2.3. Clinical Development
10.2.4. Product Profile
10.3. Idecabtagene vicleucel (bb2121): Celgene/Bluebird Bio
10.3.1. Product Description
10.3.2. Other Developmental Activities
10.3.3. Clinical Development
10.3.4. Product Profile
10.4. Isatuximab: Sanofi
10.4.1. Product Description
10.4.2. Other Developmental Activities
10.4.3. Clinical Development
10.4.4. Product Profile
10.5. LCAR-B38M BCMA CAR-T Therapy (JNJ-68284528): Legend Biotech Biotech/Janssen Biotech
10.5.1. Product Description
10.5.2. Other Developmental Activities
10.5.3. Clinical Development
10.5.4. Product Profile
10.6. Belantamab mafodotin (GSK2857916): GlaxoSmithKline
10.6.1. Product Description
10.6.2. Other Developmental Activities
10.6.3. Clinical Development
10.6.4. Product Profile
10.7. Ibrutinib: Pharmacyclics
10.7.1. Product Description
10.7.2. Other Developmental Activities
10.7.3. Clinical Development
10.7.4. Product Profile
10.8. Xpovio: Karyopharm Therapeutics
10.8.1. Drug Description
10.8.2. Regulatory Milestones
10.8.3. Other Development Activities
10.8.4. Safety and Efficacy
10.8.5. Pipeline Activity
10.8.6. Product Profile

11. Relapsing Refractory Multiple Myeloma: 10 Emerging Market (EM) Analysis
11.1. Key Findings
11.2. Market Size of Relapsing Refractory Multiple Myeloma in 10 EM

12. Market Outlook
12.1. What do Experts say??
12.2. East Asia: China and Taiwan
12.2.1. China Market Size
12.2.1.1. Total Market size of Relapsing Refractory Multiple Myeloma
12.2.1.2. Current Market Size by Therapies
12.2.1.3. Emerging Market Size by Therapies
12.2.2. Taiwan Market Size
12.2.2.1. Total Market size of Relapsing Refractory Multiple Myeloma
12.2.2.2. Current Market Size by Therapies
12.2.2.3. Emerging Market Size by Therapies
12.3. Middle East: Saudi Arabia and the United Arab Emirates
12.3.1. Saudi Arabia Market Size
12.3.1.1. Total Market size of Relapsing Refractory Multiple Myeloma
12.3.1.2. Current Market Size by Therapies
12.3.1.3. Emerging Market Size by Therapies
12.3.2. United Arab Emirates Market Size
12.3.2.1. Total Market size of Relapsing Refractory Multiple Myeloma
12.3.2.2. Current Market Size by Therapies
12.3.2.3. Emerging Market Size by Therapies
12.4. Eastern Europe: Russia and Turkey
12.4.1. Russia Market Size
12.4.1.1. Total Market size of Relapsing Refractory Multiple Myeloma
12.4.1.2. Current Market Size by Therapies
12.4.1.3. Emerging Market Size by Therapies
12.4.2. Turkey Market Size
12.4.2.1. Total Market size of Relapsing Refractory Multiple Myeloma
12.4.2.2. Current Market Size by Therapies
12.4.2.3. Emerging Market Size by Therapies
12.5. Latin America (LATAM): Argentina, Brazil, Colombia, Mexico
12.5.1. Mexico Market Size
12.5.1.1. Total Market size of Relapsing Refractory Multiple Myeloma
12.5.1.2. Current Market Size by Therapies
12.5.1.3. Emerging Market Size by Therapies
12.5.2. Brazil Market Size
12.5.2.1. Total Market size of Relapsing Refractory Multiple Myeloma
12.5.2.2. Current Market Size by Therapies
12.5.2.3. Emerging Market Size by Therapies
12.5.3. Argentina Market Size
12.5.3.1. Total Market size of Relapsing Refractory Multiple Myeloma
12.5.3.2. Current Market Size by Therapies
12.5.3.3. Emerging Market Size by Therapies
12.5.4. Colombia Market Size
12.5.4.1. Total Market size of Relapsing Refractory Multiple Myeloma
12.5.4.2. Current Market Size by Therapies
12.5.4.3. Emerging Market Size by Therapies

13. Market Drivers

14. Market Barriers

15. Appendix
15.1. Report Methodology

16. Capabilities

17. Disclaimer

18. About the Publisher
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll